Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development
NTRK1/2/3 fusions have recently been characterized as low incidence oncogenic alterations across various tumor histologies. Tyrosine kinase inhibitors (TKIs) of the tropomyosin receptor kinase family TrkA/B/C (encoded by NTRK1/2/3) are showing promises in the clinic for the treatment of cancer patie...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 April 2017
|
| In: |
Bioorganic & medicinal chemistry letters
Year: 2017, Jahrgang: 27, Heft: 12, Pages: 2771-2775 |
| ISSN: | 1464-3405 |
| DOI: | 10.1016/j.bmcl.2017.04.064 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.bmcl.2017.04.064 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0960894X17304419 
|
| Verfasserangaben: | Vadim Bernard-Gauthier, Anne Mahringer, Matthew Vesnaver, Gert Fricker, Ralf Schirrmacher |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575296381 | ||
| 003 | DE-627 | ||
| 005 | 20230427042905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180518s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bmcl.2017.04.064 |2 doi | |
| 035 | |a (DE-627)1575296381 | ||
| 035 | |a (DE-576)505296381 | ||
| 035 | |a (DE-599)BSZ505296381 | ||
| 035 | |a (OCoLC)1341009897 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bernard-Gauthier, Vadim |e VerfasserIn |0 (DE-588)1159777292 |0 (DE-627)1022455362 |0 (DE-576)42821732X |4 aut | |
| 245 | 1 | 0 | |a Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development |c Vadim Bernard-Gauthier, Anne Mahringer, Matthew Vesnaver, Gert Fricker, Ralf Schirrmacher |
| 264 | 1 | |c 21 April 2017 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.05.2018 | ||
| 520 | |a NTRK1/2/3 fusions have recently been characterized as low incidence oncogenic alterations across various tumor histologies. Tyrosine kinase inhibitors (TKIs) of the tropomyosin receptor kinase family TrkA/B/C (encoded by NTRK1/2/3) are showing promises in the clinic for the treatment of cancer patients whose diseases harbor NTRK tumor drivers. We describe herein the development of [18F]QMICF ([18F]-(R)-9), a quinazoline-based type-II pan-Trk radiotracer with nanomolar potencies for TrkA/B/C (IC50=85-650nM) and relevant TrkA fusions including TrkA-TPM3 (IC50=162nM). Starting from a racemic FLT3 (fms like tyrosine kinase 3) inhibitor lead with off-target TrkA activity ((±)-6), we developed and synthesized the fluorinated derivative (R)-9 in three steps and 40% overall chemical yield. Compound (R)-9 displays a favorable selectivity profile on a diverse set of kinases including FLT3 (>37-fold selectivity for TrkB/C). The mesylate precursor 16 required for the radiosynthesis of [18F]QMICF was obtained in six steps and 36% overall yield. The results presented herein support the further exploration of [18F]QMICF for imaging of Trk fusions in vivo. | ||
| 650 | 4 | |a Fluorine-18 | |
| 650 | 4 | |a Positron emission tomography (PET) | |
| 650 | 4 | |a Radiochemistry | |
| 650 | 4 | |a Tropomyosin receptor kinases | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 700 | 1 | |a Mahringer, Anne |e VerfasserIn |0 (DE-588)143168827 |0 (DE-627)704409607 |0 (DE-576)335452981 |4 aut | |
| 700 | 1 | |a Fricker, Gert |d 1956- |e VerfasserIn |0 (DE-588)1042227675 |0 (DE-627)768469465 |0 (DE-576)393783464 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioorganic & medicinal chemistry letters |d Amsterdam [u.a.] : Elsevier Science, 1991 |g 27(2017), 12, Seite 2771-2775 |h Online-Ressource |w (DE-627)306717522 |w (DE-600)1501505-1 |w (DE-576)110916573 |x 1464-3405 |7 nnas |a Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development |
| 773 | 1 | 8 | |g volume:27 |g year:2017 |g number:12 |g pages:2771-2775 |g extent:5 |a Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bmcl.2017.04.064 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0960894X17304419 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180518 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1042227675 |a Fricker, Gert |m 1042227675:Fricker, Gert |d 160000 |d 160100 |e 160000PF1042227675 |e 160100PF1042227675 |k 0/160000/ |k 1/160000/160100/ |p 4 | ||
| 998 | |g 143168827 |a Mahringer, Anne |m 143168827:Mahringer, Anne |d 160000 |d 160100 |e 160000PM143168827 |e 160100PM143168827 |k 0/160000/ |k 1/160000/160100/ |p 2 | ||
| 999 | |a KXP-PPN1575296381 |e 3009779712 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development","title_sort":"Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development"}],"language":["eng"],"person":[{"given":"Vadim","role":"aut","display":"Bernard-Gauthier, Vadim","family":"Bernard-Gauthier"},{"display":"Mahringer, Anne","given":"Anne","role":"aut","family":"Mahringer"},{"family":"Fricker","display":"Fricker, Gert","role":"aut","given":"Gert"}],"name":{"displayForm":["Vadim Bernard-Gauthier, Anne Mahringer, Matthew Vesnaver, Gert Fricker, Ralf Schirrmacher"]},"id":{"doi":["10.1016/j.bmcl.2017.04.064"],"eki":["1575296381"]},"physDesc":[{"extent":"5 S."}],"relHost":[{"recId":"306717522","origin":[{"publisher":"Elsevier Science","dateIssuedDisp":"1991-","dateIssuedKey":"1991","publisherPlace":"Amsterdam [u.a.]"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Bioorganic and medicinal chemistry letters"}],"note":["Gesehen am 09.11.2020"],"disp":"Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer developmentBioorganic & medicinal chemistry letters","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["306717522"],"issn":["1464-3405"],"zdb":["1501505-1"]},"part":{"volume":"27","text":"27(2017), 12, Seite 2771-2775","year":"2017","pages":"2771-2775","extent":"5","issue":"12"},"language":["eng"],"title":[{"subtitle":"a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines","title":"Bioorganic & medicinal chemistry letters","title_sort":"Bioorganic & medicinal chemistry letters"}],"pubHistory":["1.1991 -"]}],"note":["Gesehen am 18.05.2018"],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"21 April 2017"}],"recId":"1575296381","type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a BERNARDGAUDESIGNANDS2120 | ||